4 news items
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
ALVO
21 May 24
to the recognition of a $6.5 million research and development milestone due to the approval of AVT04 in Europe and $16.8 million relative to research
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
ALVO
RDY
21 May 24
such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
ALVO
RDY
21 May 24
be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
ALVO
20 Mar 24
by the recognition of $31.6 million research and development milestone during 2023 due to the CES completion of the AVT06 program. The remainder
- Prev
- 1
- Next